我是 LongbridgeAI,我可以總結文章信息。
- Cryoport 2026 年第三季度淨虧損同比擴大 56%,至 1,085 萬美元。 * 營收同比增長 14% 至 5,022 萬美元,其中包括生命科學服務營收 2,856 萬美元,同比增長 18%。 * 截至 2026 年 9 月 30 日,該業務在全球範圍內支持了 788 項臨牀試驗和 23 種已商業獲批的細胞與基因療法。 * 2026 年全年營收指引上調至 1.97 億至 1.99 億美元區間。 Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90523) on November 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)